Viatris Inc. (VTRS) Stock

About Viatris Inc.

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Viatris Inc. is led by CEO Scott Andrew Smith, employs 30,000 people, headquartered in Canonsburg, US, publicly traded since 1980.

Viatris Inc. (VTRS) stock trades at $17.65 with a market capitalization of $20.55B. The stock is valued at a price-to-earnings (P/E) ratio of 6.41, price-to-book of 1.34, price-to-sales of 1.32. Over the past 52 weeks the stock has ranged between $8.19 and $17.92, and currently trades 1.5% below its 52-week high. It pays a dividend yielding 2.80%.

On profitability, Viatris Inc. generates a return on equity (ROE) of -1.96%, return on capital employed of -18.10%, an operating margin of 6.78%, a net profit margin of -2.04%.

In its most recent fiscal year, Viatris Inc. reported annual revenue of $14.3B, net profit of $-3.5B, revenue has compounded at 3.7% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.98, a current ratio of 1.60, total assets of $37.2B, $1.3B in cash and equivalents.

VTRS has an average daily trading volume of 10,920,635 shares, a beta of 0.90.

Official website: www.viatris.com